Overview
Leukodystrophy is not a single disease but a group of rare, progressive disorders that affect the white matter of the brain and spinal cord. White matter is made up of nerve fibers covered by a protective coating called myelin, which helps nerve signals travel quickly and efficiently. In leukodystrophies, myelin is either not made properly, breaks down over time, or is not maintained correctly. This disrupts communication between different parts of the brain and the rest of the body. Because there are many different types of leukodystrophy — each caused by a different genetic change — symptoms can vary widely from person to person. Common problems include difficulty walking, muscle stiffness or weakness, trouble with speech and swallowing, vision or hearing loss, seizures, and a decline in thinking and learning abilities. Some forms appear in infancy or early childhood, while others may not show up until adulthood. Treatment depends on the specific type of leukodystrophy. Some forms have targeted therapies, such as hematopoietic stem cell transplantation (bone marrow transplant) for certain types like adrenoleukodystrophy, or enzyme replacement therapy for others. However, many types currently have no cure, and care focuses on managing symptoms and improving quality of life. Research is actively ongoing, with gene therapy showing promise for several forms.
Key symptoms:
Difficulty walking or loss of ability to walkMuscle stiffness or spasticityMuscle weaknessProblems with balance and coordinationSlurred or lost speechDifficulty swallowingVision loss or abnormal eye movementsHearing lossSeizuresDecline in memory, thinking, or learningBehavioral or personality changesLoss of previously learned skills (developmental regression)Fatigue and low energyBladder or bowel control problemsAdrenal gland problems (in some types like ALD)
Variable
Can be inherited in different ways depending on the underlying gene
Variable
Can begin at different ages, from infancy through adulthood
FDA & Trial Timeline
8 eventsUniversity of California, San Diego — PHASE1, PHASE2
Massachusetts General Hospital — PHASE1, PHASE2
Genetix Biotherapeutics Inc. — NA
Minoryx Therapeutics, S.L. — PHASE3
Calico Life Sciences LLC — PHASE1, PHASE2
Children's Hospital of Philadelphia — NA
Joanne Kurtzberg, MD — PHASE1
University of Utah
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Leukodystrophy.
8 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Rare Disease Specialist
Rare Disease Specialist
Treatment Centers
8 centersChildren's Hospital of Orange County
📍 Orange, California
👤 Richard Neibeger, MD
Children's National Medical Center
📍 Washington D.C., District of Columbia
👤 Richard Neibeger, MD
Ann & Robert H. Lurie Children's Hospital of Chicago
📍 Chicago, Illinois
Nationwide Children's Hospital
📍 Columbus, Ohio
University of Minnesota
📍 Minneapolis, Minnesota
University of Pittsburgh Medical Center
📍 Pittsburgh, Pennsylvania
Mayo Clinic
📍 Jacksonville, Florida
University of Pennsylvania
📍 Philadelphia, Pennsylvania
Travel Grants
No travel grants are currently matched to Leukodystrophy.
Community
No community posts yet. Be the first to share your experience with Leukodystrophy.
Start the conversation →Latest news about Leukodystrophy
Disease timeline:
New recruiting trial: Natural History, Diagnosis, and Outcomes for Leukodystrophies
A new clinical trial is recruiting patients for Leukodystrophy
New trial: The Myelin Disorders Biorepository Project
Phase NA trial recruiting.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.Which specific type of leukodystrophy has been identified, and what does that mean for my child's or my own prognosis?,Is there an approved or experimental treatment available for this specific type, and are we eligible?,Should other family members be tested, and what are the chances of passing this on to future children?,What specialists should be part of our care team, and how often should we be seen?,Are there clinical trials we should consider, and how do we find out about new research?,What early warning signs should prompt us to seek emergency care?,What support services — such as therapy, school accommodations, or home care — are available to us?
Common questions about Leukodystrophy
What is Leukodystrophy?
Leukodystrophy is not a single disease but a group of rare, progressive disorders that affect the white matter of the brain and spinal cord. White matter is made up of nerve fibers covered by a protective coating called myelin, which helps nerve signals travel quickly and efficiently. In leukodystrophies, myelin is either not made properly, breaks down over time, or is not maintained correctly. This disrupts communication between different parts of the brain and the rest of the body. Because there are many different types of leukodystrophy — each caused by a different genetic change — symptom
Are there clinical trials for Leukodystrophy?
Yes — 8 recruiting clinical trials are currently listed for Leukodystrophy on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Leukodystrophy?
25 specialists and care centers treating Leukodystrophy are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.